Abstract
Aim . To study the antihypertensive and hypolipidemic effect of therapy based on perindopril, including its combinations, and rosuvastatin in real clinical practice. Material and methods . Analysis of the medical records of patients observed for hypertension (HT) and treated with perindopril, amlodipine and rosuvastatin in the multicenter nonintervention SYNERGY study was performed. Patients with established diagnosis of HT and registered elevated cholesterol blood level were included into the study. The drugs were prescribed by doctors in different doses. Data on the disease history, physical status, blood pressure (BP) measurements, and lipid blood levels were taken from the patient's medical records. Results. 1736 patients (53% of women) with the mean age of 58.7 years were included into the analysis. 1322 patients (76.2%) previously received antihypertensive therapy, and 807 (46.5%) – lipid-lowering therapy. Reduction in systolic and diastolic BP, low density cholesterol blood level was found at the end of the study in all study groups s (p<0.05). This demonstrated an adequate antihypertensive and lipid-lowering effect of the applied treatment regimens. The average decrease in systolic BP was from 20.5 to 41.4 mm Hg, and this in diastolic BP – from 8.8 to 22.2 mm Hg. The maximum reduction in systolic BP was found in the group of perindopril 8 mg+amlodipine 10 mg+rosuvastatin 5 mg (41.4 mm Hg), and this in diastolic BP – in the group of perindopril 8 mg+rosuvastatin 10 mg. The mean decrease in low density cholesterol blood level was from 0.74 mmol/L in the group of perindopril 4 mg+amlodipine 10 mg+rosuvastatin 5 mg up to 1.75 mmol/l in the group of perindopril 8 mg+amlodipine 10 mg+rosuvastatin 20 mg Conclusion: Therapy with perindopril, amlodipine and rosuvastatin resulted in significant reduction in BP and low-density cholesterol blood level in all the treatment groups. The study of the efficacy of combined therapy in patients with HT and dyslipidemia in real clinical practice makes it possible to evaluate the potential contribution of pharmacotherapy in reducing the risk of cardiovascular complications.
Highlights
Всего в анализ было включено 1736 пациентов (53% женщин); средний возраст 58,7 лет. 1322 пациента (76,2%) ранее получали антигипертензивную терапию и 807 (46,5%) – липидоснижающую терапию
1736 patients (53% of women) with the mean age of 58.7 years were included into the analysis. 1322 patients (76.2%) previously received antihypertensive therapy, and 807 (46.5%) – lipid-lowering therapy
Mourad J.J. The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target
Summary
Был проведен анализ карт пациентов, получавших лечение периндоприлом, амлодипином и розувастатином в рамках многоцентрового исследования СИНЕРГИЯ [10]. При сравнении групп лечения показатель САД был основным критерием оценки эффективности в отношении снижения артериального давления. Исходные демографические и клинические характеристики были обобщены в группах лечения с использованием соответствующих методов описательной статистики. Группы ПАР (с одинаковой дозой периндоприла и амлодипина, независимо от дозы розувастатина) были объединены для проведения анализа САД и ДАД. Подобным образом группы ПАР с одинаковой дозой розувастатина (независимо от дозы периндоприлаи амлодипина) были объединены с целью проведения анализа динамики уровней ХС ЛПНП. Большинство пациентов получали лечение всеми тремя лекарственными препаратами (периндоприл, амлодипин, розувастатин), тогда как некоторые получали комбинацию периндоприла и розувастатина или монотерапию периндоприлом. Группа лечения ПАР, получавшая 8 мг периндоприла и 10 мг амлодипина, включала пациентов с более
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
